ReviewThoracic cancer2022
Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.
Review in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Epstein-Barr virus-driven molecular pathogenesis of primary pulmonary lymphoepithelial carcinoma.Frontiers in oncology · 2025Review
- [Clinicopathological Analysis of 14 Cases of Primary Pulmonary Lymphoepithelial Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series.Translational lung cancer research · 2024Article
- Metastatic stomach lymphoepithelioma-like carcinoma and immune checkpoint inhibitor therapy: A case report.World journal of gastrointestinal surgery · 2024Article
- Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival.Anti-cancer agents in medicinal chemistry · 2024Article
- Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study.Translational lung cancer research · 2023Article
- Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital.Frontiers in oncology · 2023Article
- Pathogenesis and therapeutic implications of EBV-associated epithelial cancers.Frontiers in oncology · 2023Review
- Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.Thoracic cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we report a case of metastatic Epstein-Barr virus (EBV)-related primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibitors (ICIs). This is the first case report of a favorable outcome to ICIs in the late-line treatment of advanced PPLELC patients with programmed cell death-ligand 1 (PD-L1) expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.